Stock Market Reviews

TCRX (TScan Therapeutics, Inc.) News

Get the latest news, insights, and market updates on TCRX (TScan Therapeutics, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Arvinas, Inc. (ARVN) Reports Q3 Loss, Tops Revenue Estimates
  Arvinas (ARVN) delivered earnings and revenue surprises of +36.00% and +55.31%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
  Nov 5, 2025 - $TCRX
• TScan Therapeutics Reaches Agreement with FDA on Pivotal Study Design for TSC-101 and Announces Strategic Prioritization to Advance TSC-101 and Extend Cash Runway into H2 2027
  Positive end of Phase I meeting and agreement reached with FDA on pivotal study design for TSC-101 Dosed first solid tumor patients with multiplex TCR-T therapy; paused further enrollment to prioritize heme development; reiterates planned data readout in Q1 2026 Enacted ~30% workforce reduction to focus clinical development on heme program and initiate pre-clinical development of in vivo-engineered TCR-T for solid tumors Strategic prioritization extends cash runway into H2 2027 Conference call a
  Nov 3, 2025 - $TCRX
• Alnylam Pharmaceuticals (ALNY) Q3 Earnings and Revenues Top Estimates
  Alnylam (ALNY) delivered earnings and revenue surprises of +73.65% and +22.25%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
  Oct 30, 2025 - $TCRX
• 2 Overlooked Stocks to Snap Up in 2025
  While much of Wall Street’s attention in 2025 centers around AI names, two under-the-radar companies are quietly getting stronger.
  Oct 16, 2025 - $TCRX
• TScan Therapeutics Announces Upcoming Oral and Poster Presentations at the American College of Rheumatology Convergence 2025
  Highlights discovery of novel targets in T cell-driven autoimmune disorders; initial findings to be presented at the ACR Convergence 2025WALTHAM, Mass., Sept. 17, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced the acceptance of two abstracts, one as an oral presentation and another as a poster
  Sep 17, 2025 - $TCRX
• TScan Therapeutics to Participate in Upcoming Investor Conferences
  WALTHAM, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will participate in the following upcoming investor conferences: Morgan Stanley 23rd Annual Global Healthcare Conference; the fireside chat will be held at the Sheraton New York Times Square on Tuesday, Se
  Sep 3, 2025 - $TCRX
• TScan Therapeutics (NASDAQ:TCRX) Will Have To Spend Its Cash Wisely
  NasdaqGM:TCRX 1 Year Share Price vs Fair Value Explore TScan Therapeutics's Fair Values from the Community and select...
  Aug 15, 2025 - $TCRX
• TScan Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
  Two-year relapse data from ALLOHA™ Phase 1 heme trial to be presented by end of year Expects to dose first solid tumor patients with multiplex TCR-T in the third quarter of 2025 Cash, cash equivalents, and marketable securities continue to fund operations into the first quarter of 2027 WALTHAM, Mass., Aug. 12, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) thera
  Aug 12, 2025 - $TCRX
• TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Beats Revenue Estimates
  TScan Therapeutics (TCRX) delivered earnings and revenue surprises of 0.00% and +58.07%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
  Aug 12, 2025 - $TCRX
• Urogen Pharma (URGN) Reports Q2 Loss, Lags Revenue Estimates
  Urogen Pharma (URGN) delivered earnings and revenue surprises of -28.05% and -0.96%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
  Aug 7, 2025 - $TCRX